ANDA 203603, held by Cardinal Health 414. Fludeoxyglucose F-18.
As of Nov 16, 2026, ANDA 203603 (Fludeoxyglucose F18), held by Cardinal Health 414, was first approved by FDA on Nov 13, 2015, with 1 approved supplement and 0 published complete response letters.
Fludeoxyglucose F-18 Injection is indicated for positron emission tomography (PET) imaging in the following settings:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 13, 2015 | Original application | Approved | None posted |
| Fludeoxyglucose F1820-300mCi/ML · injectable;intravenous | Fludeoxyglucose F-18 | Rx |
| Fludeoxyglucose F1820-500mCi/ML · injectable;intravenous | Fludeoxyglucose F-18 | Rx |
| Sep 27, 2018 | Supplement 7Manufacturing | Approved | None posted |
| Nov 13, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters